Pathfi nder shows the way niversal screening for meticillin resistant Staphyloccus aureus (MRSA) is controversial. The implementation of screening for all elective admissions, and more recently emergency admissions, has a major fi nancial impact on NHS trusts across England. Decolonisation of those patients who screen positive and in the case of emergency admissions isolation or cohorting of patients also creates pressure in the care system. Many infection prevention practitioners question the cost-effectiveness of the current strategy in England and colleagues are heard in heated discussions about the perceived waste of resources when faced with the potential loss of members of the infection prevention team and laboratory services.
Following a Health Technology Assessment ( Ritchie et al, 2007 ) NHS Scotland chose to test the features of universal MRSA screening against the requirements for public health screening programmes prior to its wholesale implementation. A prospective impact assessment designated as the MRSA Screening Pathfi nder Programme was commenced in August 2008 and interim fi ndings were published in spring 2009, with the completed programme scheduled to report in December 2009. The one-year programme of prospective linked projects aimed to: establish the clinical effectiveness of universal screening using chromogenic agar test the assumptions used in the Health Technology Assessment ( Ritchie et al, 2007 ) economic model assess the acceptability of screening to patients and staff evaluate the feasibility of extending MRSA screening to the non pathfi nder boards.
The long awaited fi ndings of the Pathfi nder Programme along with the fi ndings of two additional studies and updated reports were fi nally published in February 2011 ( Health Protection Society (HPS), 2009a , 2009b , 2009c , 2009d , 2010a , 2010b , 2010c Reilly et al, 2011 ; Stewart et al, 2010 Stewart et al, , 2011 and provide truly comprehensive economic and impact analyses that are important milestones in our effort to reduce MRSA infections.
So what has been learned from the Pathfi nder Programme and how can it help us to further reduce the carriage of MRSA in an effi cient and cost-effective way? Here are some of the highlights, but if you have not already done so I recommend that you read the reports in full.
The report ( HPS, 2009a ) indicates that Scotland has a similar experience to England and Wales with a downward trend in both MRSA colonisation and infection. The incidence of MRSA infection was 7.5 per 1000 patient days over the year. The prevalence of MRSA colonisation reduced from 5.5 % to 3.5 % and incidence also reduced signifi cantly in the pathfi nder boards over the 12 months of the study. Nasal carriage also decreased over the period of the study and has levelled out at 2% as predicted in the fi nal report ( HPS 2009a ( HPS , 2010a .
Perhaps the most important message from the reports is that like many infection prevention interventions there is no simple or magical solution to preventing MRSA infections. We now know more than we did but there is still more to investigate. Universal laboratory based screening and associated decolonisation and isolation of patients is only one of the solutions to preventing U MRSA infection in a cost-effective way. Even the most effective low cost test is expensive, is not as effective as we believed, and has infrastructure and resource implications for healthcare providers.
Unsurprisingly we learn that a screening programme does not prevent MRSA infection. In the pathfi nder boards half of the MRSA infections detected were in patients who had screened negative on admission to hospital. This suggests that we are still not applying infection control precautions effectively and that cross transmission occurs as a result (HPS, 2009a) . The sensitivity of the screening test and single site swabs were suggested as factors that might be associated with this fi nding. A subsequent study identifi ed that nasal swabbing alone was less effective than previously thought against the 'gold standard' ( HPS, 2010a ) .
The feasibility of screening on admission and the subsequent isolation and completion of decolonisation treatment on the basis of a timely laboratory result was also found to be a huge challenge (HPS, 2009a) . The report indicates that decolonisation was started in 44 % of patients screened on admission and only 46 % in those screened pre-admission. In addition only 3% of patients who were found to be MRSA positive completed their decolonisation regimen and half of the patients who were found to be positive were not able to be isolated. The factors associated with these fi ndings were short hospital stay with some patients being discharged before the result was known, and shortages of single rooms. However the authors suggest that even incomplete decolonisation has some benefi cial effect (2.7 versus 4.2 infections per 1000 patient days).
The four fi nal 2009 reports raised a number of questions that were the subject of additional studies. These focused on the use of clinical risk assessment strategies (CRA) and their economic costs and also a discharge screening study to estimate how many patients acquire MRSA while in hospital. The results of the fi rst indicates that Universal CRA is as effective as Universal Laboratory Screening and can be used to identify those patients at risk of MRSA colonisation to better target laboratory screening and more importantly clinical management to ensure that concomitant interventions are initiated and completed (HPS, 2010a) . The second tells us that we are still not getting the basics and the organisational issues right and that we should consider how to best manage colonisation in patients who are frequently admitted to hospital ( HPS, 2010b ). The resulting updated and Situation-Background-Assessment-Recommendation (SBAR) reports ( HPS, 2010c ; Reilly et al, 2011 ; Stewart et al, 2011 ) have led the Scottish government to implement the most evidence-based policy strategy for MRSA screening to date. Is the book open on how long it will take the other administrations to follow suit?
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